An observational study in Hepatocellular Carcinoma, sponsored by Yonsei University. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-17.
Sponsored by Yonsei University · Observational
There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used
There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used
6,741 studies on the registry are indexed under Carcinoma; 1,163 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Yonsei University is the lead sponsor of 1,387 studies on the registry; 232 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Liver cirrhosis
Exclusion Criteria:
PIVKA-II and AFP measurement every 6 months
tumor maker interval every 6 month
Device: tumor maker interval shortly
tumor maker interval every 3 month
Also known as: tumor maker interval every 3 month
the difference of curative treatments & survival rates
Time frame: 4 years
the difference of early detection rates of HCC between both groups
Time frame: 4 years
This study is status unknown, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yonsei University